Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 120

1.

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD.

Leukemia. 2019 Aug 27. doi: 10.1038/s41375-019-0552-3. [Epub ahead of print] No abstract available.

PMID:
31455850
2.

Development of an Instrument to Assess Work Productivity in Individuals With Voice Disorders: The Work Hoarse.

Zhu Q, Hu A, Giliberto JP, Carlson S, Jensen S, Tiu R, Meyer TK.

Ann Otol Rhinol Laryngol. 2019 Jan;128(1):5-12. doi: 10.1177/0003489418803961. Epub 2018 Oct 12.

PMID:
30311497
3.

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma.

Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, Tiu RV, Pitou C, Tucker T, Brail L, Von Hoff D.

Clin Cancer Res. 2018 May 1;24(9):2082-2091. doi: 10.1158/1078-0432.CCR-17-0723. Epub 2018 Feb 26.

4.

Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

Palam LR, Mali RS, Ramdas B, Srivatsan SN, Visconte V, Tiu RV, Vanhaesebroeck B, Roers A, Gerbaulet A, Xu M, Janga SC, Takemoto CM, Paczesny S, Kapur R.

JCI Insight. 2018 Feb 22;3(4). pii: 94679. doi: 10.1172/jci.insight.94679. eCollection 2018 Feb 22.

5.

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.

Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB.

Oncogene. 2018 Feb 8;37(6):821-832. doi: 10.1038/onc.2017.384. Epub 2017 Oct 23.

PMID:
29059158
6.

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.

Yao YM, Donoho GP, Iversen PW, Zhang Y, Van Horn RD, Forest A, Novosiadly RD, Webster YW, Ebert P, Bray S, Ting JC, Aggarwal A, Henry JR, Tiu RV, Plowman GD, Peng SB.

Clin Cancer Res. 2017 Sep 15;23(18):5547-5560. doi: 10.1158/1078-0432.CCR-16-3250. Epub 2017 Jun 13.

7.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

PMID:
28602585
8.

Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.

Smith C, Lee V, Schuessler A, Beagley L, Rehan S, Tsang J, Li V, Tiu R, Smith D, Neller MA, Matthews KK, Gostick E, Price DA, Burrows J, Boyle GM, Chua D, Panizza B, Porceddu SV, Nicholls J, Kwong D, Khanna R.

Oncoimmunology. 2017 Jan 4;6(2):e1273311. doi: 10.1080/2162402X.2016.1273311. eCollection 2017.

9.

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.

Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL Jr, Tiu RV, Wang X, Callies S, Cox J, Tuttle JL, Lau YK, Roeland EJ.

J Hematol Oncol. 2017 Mar 21;10(1):73. doi: 10.1186/s13045-017-0427-x.

10.

Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma.

Hung IF, Wong DK, Poon RT, Fong DY, Chui AH, Seto WK, Fung JY, Chan AC, Yuen JC, Tiu R, Choi O, Lai CL, Yuen MF.

PLoS One. 2016 Feb 22;11(2):e0148493. doi: 10.1371/journal.pone.0148493. eCollection 2016.

11.

Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.

Hamilton BK, Visconte V, Jia X, Tabarroki A, Makishima H, Hasrouni E, Abounader D, Kalaycio M, Sekeres MA, Sobecks R, Duong Liu H, Bolwell B, Maciejewski JP, Copelan E, Tiu RV.

Am J Hematol. 2016 Jun;91(4):406-9. doi: 10.1002/ajh.24306. Epub 2016 Mar 14.

12.

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF.

Haematologica. 2015 Sep;100(9):1117-30. doi: 10.3324/haematol.2014.114660.

13.

Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

Ai J, Visconte V, Tabarroki A, Hasrouni E, Hamilton BK, Mukherjee S, Kalaycio M, Sobecks R, Advani AS, Sekeres MA, Shetty S, Tiu RV.

Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):489-95. doi: 10.1016/j.clml.2015.03.017. Epub 2015 Apr 2.

PMID:
25977195
14.

Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.

Shomali W, Redmond C, Bogati S, Zimmerman C, Visconte V, Tabarroki A, Kalaycio M, Tiu RV.

Leuk Lymphoma. 2016;57(1):193-5. doi: 10.3109/10428194.2015.1036259. Epub 2015 Jun 18. No abstract available.

PMID:
25942382
15.

Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Visconte V, Tabarroki A, Hasrouni E, Maciejewski JP, Hsi ED, Tiu RV, Rogers HJ.

Leuk Lymphoma. 2016;57(1):212-5. doi: 10.3109/10428194.2015.1045895. Epub 2015 Jun 25. No abstract available.

PMID:
25926061
16.

Current and novel therapeutic approaches in myelodysplastic syndromes.

Estephan F, Tiu RV.

J Community Support Oncol. 2014 Jul;12(7):236-49. doi: 10.12788/jcso.0057. Review.

PMID:
25830232
17.

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF; MDS/MPN International Working Group.

Blood. 2015 Mar 19;125(12):1857-65. doi: 10.1182/blood-2014-10-607341. Epub 2015 Jan 26.

18.

Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

Saunthararajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, Englehaupt R, Juersivich J, Cooper K, Husseinzadeh H, Przychodzen B, Rump M, Hobson S, Earl M, Sobecks R, Dean R, Reu F, Tiu R, Hamilton B, Copelan E, Lichtin A, Hsi E, Kalaycio M, Maciejewski J.

J Clin Invest. 2015 Mar 2;125(3):1043-55. doi: 10.1172/JCI78789. Epub 2015 Jan 26.

19.

Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy.

Ornstein MC, Mukherjee S, Keng M, Elson P, Tiu RV, Saunthararajah Y, Maggiotto A, Schaub M, Banks D, Advani A, Kalaycio M, Maciejewski JP, Sekeres MA.

Leuk Lymphoma. 2015;56(9):2536-42. doi: 10.3109/10428194.2014.1003557. Epub 2015 Feb 20.

PMID:
25563427
20.

Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.

Visconte V, Tiu RV, Rogers HJ.

Blood Res. 2014 Dec;49(4):216-27. doi: 10.5045/br.2014.49.4.216. Epub 2014 Dec 23. Review.

Supplemental Content

Support Center